News
Tharimmune, Inc., (Nasdaq:THAR) (”Tharimmune” or the “Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology announced ...
Tharimmune Inc.: Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences
BRIDGEWATER, NJ / ACCESS Newswire / May 1, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeuti ...
The latest figures from the Department for Work and Pensions (DWP) show that there were 7.5 million people across Scotland, ...
The ability to predict well in advance could allow for early intervention and prevention. Researchers have discovered five ...
New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...
To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals, Inc. at 1-844-782-ICPT or FDA at 1-800-FDA-1088 or ...
A new online petition is calling for a change to eligibility rules for Personal Independence Payment (PIP). At present, people making a new claim for PIP must be able to demonstrate that the ...
As robotic cholecystectomy, also known as gallbladder removal, becomes increasingly common, researchers have identified ...
Ipsen Biopharmaceuticals Canada Inc. today announced Health Canada has issued a Notice of Compliance with Conditions (NOC/c) approving IQIRVO® (elafibranor) for the treatment of primary biliary ...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion ...
Globally, a significant portion of adults are affected by fatty liver disease, often linked with vitamin D deficiency. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results